Evidence map›Paper›PMID 41960293›Full record

ReviewRSC advances2026

Exploring the synthesis of conduritol derivatives: strategies, challenges, and advances.

Soumyadip Malik, Amrit Krishna Mitra

Abstract readReview
In one paragraph

Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Soumyadip MalikDepartment of Chemistry, Rani Rashmoni Green University Tarakeswar Hooghly West Bengal Pin: 712410 India.
Amrit Krishna MitraDepartment of Chemistry, Government General Degree College, Singur Singur Hooghly West Bengal Pin: 712409 India amritsepistles@gmail.com +91-33-2630-0126 +91 9432164011.ORCID https://orcid.org/0000-0001-8990-0205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conduritol derivatives represent an important class of cyclitol-based molecules characterized by structural diversity, synthetic flexibility, and notable biological activity. Built on a cyclohexene core bearing multiple hydroxyl groups, conduritols have attracted sustained interest due to their potent glycosidase inhibitory properties and their occurrence in biologically active natural products such as pancratistatin and lycoricidine. The parent compound exists as six diastereomeric forms, and extensive methodological advances over recent decades have enabled access to all stereoisomers as well as a wide range of functionalized derivatives, including epoxidized, aminated, halogenated, and selectively protected analogues. Many of these compounds have shown promise as enzyme inhibitors and as leads for anticancer, antileukemic, and antimicrobial applications. Building on earlier work focused on the synthesis of conduritol stereoisomers, this review concentrates on strategies for the preparation of conduritol derivatives, emphasizing asymmetric synthesis, stereoselective functionalization, and recent developments in catalytic and green chemistry approaches. Key challenges related to regio- and stereocontrol are critically discussed, along with comparative assessments of established and emerging synthetic routes. The therapeutic relevance of conduritol derivatives, particularly in glycosidase-targeted interventions for metabolic and proliferative diseases, is also highlighted, providing an integrated perspective on current advances and future opportunities in this field. By consolidating and critically evaluating the diverse synthetic methodologies developed to date, this review aims to serve as a comprehensive resource for the research community, highlighting existing methodological gaps and guiding the design of more efficient, selective, and sustainable strategies for the synthesis and application of conduritol-based frameworks.

Identifiers

PMID41960293
PMCPMC13058809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.